Abstracts tagged "Behcet’s syndrome"

Abstract Number: 1753 • 2013 ACR/ARHP Annual Meeting
An Outcome Survey Of 40 Patients With Budd-Chiari Syndrome Due To BEHÇET’S Syndrome Followed By A Single Center
Emire Seyahi¹, SerdaL Ugurlu², Erkan Caglar³, Fatih Kantarci⁴, Abdullah Sonsuz⁵, Sebahattin Yurdakul² and Hasan Yazici², ¹Division of Rheumatology,Department of Medicine,Cerrahpasa Medical Faculty, University of Istanbul, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Division of Gastroenterology, Department of Internal Medicine, Bakirkoy Research and Training Hospital, Istanbul, Turkey, ⁴Department of Radiology, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁵Division of Gastroenterology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: Budd-Chiari syndrome is a rare complication of BS with a frequency of < 1 %, and carries a high mortality rate. In a previous…
Abstract Number: 2621 • 2013 ACR/ARHP Annual Meeting
Venous Claudication Is A Severe and Frequent Symptom In BEHCET’S Syndrome
SerdaL Ugurlu¹, Emire Seyahi¹, Veysel Oktay², Zerrin Yigit², Serdar Kucukoglu² and Hasan Yazici¹, ¹Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Department of Cardiology, Cardiology Institute, University of Istanbul, Istanbul, Turkey
Background/Purpose: In a previous cross-sectional questionnaire survey, we had shown that intermittent claudication was significantly more common among BS patients when compared to healthy controls,…
Abstract Number: 1703 • 2013 ACR/ARHP Annual Meeting
High Density Genotyping Of Immune-Related Disease Genes Identifies 7 New Susceptibility Loci For Behçet’s Disease
Masaki Takeuchi^1,2, Nobuhisa Mizuki², Akira Meguro², Michael J. Ombrello³, Colleen Satorius⁴, Yohei Kirino², Tatsukata Kawagoe², Duran Ustek⁵, Ilknur Tugal-tutkun⁶, Emire Seyahi⁷, Yilmaz Ozyazgan⁷, Shigeaki Ohno⁸, Atsuhisa Ueda², Yoshiaki Ishigatsubo², Ahmet Gül^6,9, Daniel L. Kastner⁴ and Elaine Remmers⁴, ¹Medical Genetics Branch, Inflammation Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Translational Genetics and Genomics Unit, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁵Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁷Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁸Hokkaido University Graduate School of Medicine, Hokkaido, Japan, ⁹Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Genome-wide association studies have revealed susceptibility genes for many genetically complex diseases. The Immunochip is a custom array with 196,524 markers in 186 loci…
Abstract Number: 2622 • 2013 ACR/ARHP Annual Meeting
Comparison Of Different Methods Of Skin Pathergy Test In Patients With Behçet’s Syndrome
Aysegul Lacin¹, Cigdem Atan Uzun¹, Zafer Gunendi² and Feride Gogus¹, ¹Physical Medicine and Rehabilitation, Division of Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ²Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Skin pathergy test (SPT) has a diagnostic value in Behçet’s syndrome (BS). There are different descriptions of the test which may effect its positivity rate.…
Abstract Number: 1165 • 2013 ACR/ARHP Annual Meeting
Systems Approach To The Study Of the Microbiome and Inflammatory Pathways In Oral Ulcer Tissue From Patients With Active Behςet’s Syndrome (BS)
Cailin Sibley¹, Gulen Hatemi², Yusuf Yazici³, Yin Liu⁴, Steve Brooks⁵, Hasan Yazici⁶ and Raphaela Goldbach-Mansky⁷, ¹Office of the Clinical Director, NIH / NIAMS, Bethesda, MD, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Translational Autoinflammatory Disease Section, Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ⁵NIAMS/NIH, Bethesda, MD, ⁶Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ⁷Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: Behcet's syndrome (BS) exhibits features of both innate and acquired immunity. Oral ulceration is the cardinal lesion which usually precedes other manifestations. Despite the…
Abstract Number: 2623 • 2013 ACR/ARHP Annual Meeting
A CT Evaluation Of Pulmonary and Cardiac Lesions In BEHÇET’S Syndrome Patients Without Pulmonary Symptoms
Emire Seyahi¹, Deniz Cebi Olgun², SerdaL Ugurlu¹, Idil Hanci³, Reona Takahashi⁴ and Hasan Yazici¹, ¹Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Department of Radiology,, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Neurology, Krankrenhaus Nordwest, Frankfurt am Main, Frankfurt, Germany, ⁴Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: In Behçet’s syndrome (BS) patients with symptomatic pulmonary artery involvement (PAI) varying and multiple pulmonary parenchymal and cardiac lesions can be seen in thorax CT…
Abstract Number: 893 • 2013 ACR/ARHP Annual Meeting
Association Between Human Leukocyte Antigen-B’s Amino Acid Variation and Disease-Susceptibility To Takayasu’s Arteritis
Hajime Yoshifuji¹, Chikashi Terao², Kosaku Murakami³, Daisuke Kawabata³, Koichiro Ohmura¹, Takao Fujii⁴, Yasushi Kawaguchi⁵, Hisashi Yamanaka⁵ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ³Dept of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: HLA-B52 and HLA-B51 are frequently seen in Asian population and are almost identical except two amino acid residues(the 63rd and 67th), but HLA-B52 is…
Abstract Number: 2624 • 2013 ACR/ARHP Annual Meeting
Evaluation of Asymptomatic Venous Disease By Venous Doppler Ultrasonography in Patients With Behcet’s Disease
Fatma Alibaz-Oner¹, Emrah Karatay², Ihsan Nuri Akpinar², Tülin Ergun³ and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Radiology, Marmara University, School of Medicine, Istanbul, Turkey, ³Dermatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: One of the major causes of mortality and morbidity in Behcet’s disease (BD), especially in young males of Mediterranean origin, is vascular involvement. A…
Abstract Number: 2625 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy In Refractory Uveitis Of Behcet’s Syndrome: Switching and Dose Modification. Multicenter Study Of 124 Patients
F. Ortiz-Sanjuán¹, Vanesa Calvo-Río², Ricardo Blanco³, Emma Beltrán⁴, Juan Sánchez-Bursón⁵, Marina Mesquida⁶, Alfredo M. Adan⁶, M Hernandez Grafella⁷, E Valls Pascual⁸, L Martínez-Costa⁹, A Sellas-Fernàndez¹⁰, Miguel Cordero-Coma¹¹, Manuel Diaz-llopis¹², David Salom¹², Jl García Serrano¹³, Norberto Ortego¹³, JM Herreras¹⁴, Alejandro Fonollosa¹⁵, A Aparicio¹⁶, O Maíz¹⁷, A Blanco¹⁸, I Torre¹⁹, Cruz Fernández-Espartero²⁰, V Jovani²¹, D Peitado-Lopez²², Esperanza Pato²³, J Cruz²⁴, J. Carlos Fernandez-Cid²⁵, Elena Aurrecoechea²⁶, M García²⁷, M Caracuel²⁸, Carlos Montilla²⁹, A Atanes³⁰, F Francisco³¹, S Insua³², S González-Suárez³³, A Sánchez-Andrade³⁴, F Gamero³⁵, Luis Linares³⁶, F Romero-Bueno³⁷, J García³⁸, AJ García González³⁹, Raquel Almodovar⁴⁰, E Minguez⁴¹, C Carrasco Cubero⁴², Alejandro Olivé Marqués⁴³, J Vázquez⁴⁴, O Ruiz Moreno⁴⁵, F Jimenez-Zorzo⁴⁵, J Manero⁴⁵, Javier Loricera² and Miguel Angel González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Marques de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁵Hospital de Valme. Sevilla, Sevilla, Spain, ⁶Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁷Ophthalmology, Hospital General Universitario, Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Peset Valencia, Valencia, Spain, ⁹Ophthalmology, Hospital Peset Valencia, Valencia, Spain, ¹⁰Rheumatology, Hospital Val d´Hebron. Barcelona, Barcelona, Spain, ¹¹Departament of Ophthalmology, Hospital de León, León, Spain, ¹²Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain, ¹³Hospital San Cecilio. Granada, Granada, Spain, ¹⁴Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, ¹⁵Ophtalmology Service, Hospital de Cruces. Bilbao, Baracaldo, Spain, ¹⁶Rheumatology., Hospital de Toledo., Toledo, Spain, ¹⁷Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁸Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁹Rheumatology., Hospital Basurto. Bilbao, Bilbao, Spain, ²⁰Servicio de Reumatología, Hospital Universitario de Móstoles. Madrid, Madrid, Spain, ²¹Rheumatology., Hospital General de Alicante., Alicante, Spain, ²²Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, ²³Rheumatology, Hospital Clínico San Carlos. Madrid, Madrid, Spain, ²⁴Rheumatology, Hospital de Pontevedra, Pontevedra, Spain, ²⁵Departament of Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, ²⁶Rheumatology, Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁷Rheumatology., Hospital La Princesa. Madrid, Madrid, Spain, ²⁸Rheumatology., Hospital de Córdoba., Córdoba, Spain, ²⁹Rheumatology Service, Hospital Universitario de Salamanca, Salamanca, Spain, ³⁰Rheumatology., HUCA La Coruña., A Coruña, Spain, ³¹Rheumatology., Hospital Doctor Negrín Canarias., Canarias, Spain, ³²Rheumatology., Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, ³³Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, ³⁴Rheumatology., Hospital Lucus Augusti Lugo, Lugo, Spain, ³⁵Rheumatology., Hospital San Pedro Alcantara Caceres, Caceres, Spain, ³⁶Rheumatology, Hospital Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, ³⁷Rheumatology., Fundación Jimenez Díaz. Madrid, Madrid, Spain, ³⁸Rheumatology, Hospital 12 de Octubre. Madrid, Madrid, Spain, ³⁹Rheumatology., Hospital 12 de Octubre. Madrid, Madrid, Spain, ⁴⁰Rheumatology Unit, Hospital Universitario Fundación Alcorcón. Madrid, Alcorcon. Madrid, Spain, ⁴¹Ophthalmology, Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴²Rheumatology., Hospital de Mérida, Mérida, Spain, ⁴³Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain, ⁴⁴Rheumatology, Hospital de Ferrol. A Coruña, A Coruña, Spain, ⁴⁵Hospital Universitario Miguel Servet. Zaragoza, Zaragoza, Spain
Background/Purpose: Several situations can be observed in patients undergoing biologic therapy in uveitis associated to Behçet´s syndrome (BS): a) Patients are switched to another therapy…
Abstract Number: 2627 • 2013 ACR/ARHP Annual Meeting
Prognostic Factors Of Visual Function In The Treatment With Infliximab For Uveitis Of Behçet’s Disease
Akihiko Nakabayashi¹, Toru Hirano², Yoshihiro Hishitani², Keisuke Hagihara³, Kei Nakai⁴, Kouji Nishida⁴ and Atsushi Kumanogoh², ¹Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, ²Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, ³Department of Kampo Medicine, Osaka University Graduate School of Medicine, Suita, Japan, ⁴Department of Ophthalmology, Osaka University Graduate School of Medicine, suita, Japan
Background/Purpose: Infliximab, a chimeric monoclonal antibody against TNF-a, is expected to improve prognosis of visual function in patients with severe and refractory uveitis of Behçet's…
Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Mitsuhiro Takeno¹, Kayo Terauchi¹, Yohei Kirino^1,2, Ryusuke Yoshimi¹, Nobuhisa Mizuki², Etsuko Shibuya³ and Yoshiaki Ishigatsubo², ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…
Abstract Number: 2629 • 2013 ACR/ARHP Annual Meeting
Is Complete Remission a Realistic Target With Current Therapeutic Options in Behçet’s Disease ?
Fatma Alibaz-Oner¹, Gonca Mumcu², Zeynep Kubilay³, Gülsen Ozen⁴, Gülce Celik³, Aslı Karadeniz³, Meryem Can⁵, Sibel Yılmaz Oner¹, Nevsun Inanc⁶, Pamir Atagunduz⁷, Tülin Ergun⁸ and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ³Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey, ⁴Rheumatology, Marmara University School of Medicine., Istanbul, Turkey, ⁵Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Marmara University School of Medicine, Istanbul, Turkey, ⁷Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ⁸Dermatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: The clinical course of Behcet’s disease (BD) as a multi-systemic disorder with a remitting-relapsing nature is unsufficiently explored. As complete remission should be aimed…
Abstract Number: 2631 • 2013 ACR/ARHP Annual Meeting
Fertility In Behçet’s Syndrome: Structured Interview In A Multidisciplinary Center
Caner Saygin¹, Didem Uzunaslan¹, Gulen Hatemi², Koray Tascilar¹ and Hasan Yazici³, ¹University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³Cerrahpasa Medical Faculty University of Istanbul, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: Behçet’s Syndrome (BS) follows an active course during the child-bearing years in both men and women. Whether fertility is decreased among the BS patients…
Abstract Number: 2632 • 2013 ACR/ARHP Annual Meeting
Long Term Outcome Of Neuro-Behçet’s Disease
Nicolas Noel¹, Remy Bernard², Bertrand Wechsler³, Matthieu Resche-Rigon², Du Boutin⁴, Jean-Charles Piette⁵, Aurélie Drier⁶, Didier Dormont⁶, Patrice Cacoub⁴ and David Saadoun⁷, ¹APHP, Hopital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Le Kremlin Bicêtre, France, ²Biostatistics, Hopital Saint-Louis, Paris, France, ³Internal Medecine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ⁶Neuroradiology, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁷DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France
Background/Purpose: Neurological involvement occurs in 5.3 to up to 59% of patients with Behçet’s disease (BD). Although the clinical and imaging features of neuro-Behçet’s disease…
Abstract Number: 2613 • 2013 ACR/ARHP Annual Meeting
NF-κB Pathway Is Depleted In Phagocytes From Behçet´s Disease Patients Secondarily To Constitutive Phosphorylation Of The p65 Subunit
Sandro F. Perazzio^1,2, Paulo Vitor Soeiro Pereira³, Alexandre W.S. Souza^4,5, Antonio Condino-Neto³ and Luis Eduardo C. Andrade⁶, ¹Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Fleury Medicine and Health, Sao Paulo, Brazil, ³Immunology, ICB IV - Universidade de São Paulo, São Paulo, Brazil, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: : Increased neutrophil activation has been previously shown in Behçet’s disease (BD) patients and it is unclear whether neutrophil activation occurs constitutively or if…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.